Dr. Reddy’s Laboratories reported a weaker second quarter for FY2027, with both revenue and profit after tax declining from the previous year. The company posted revenue of ₹8,671 crore, down 1.5%, while profit after tax fell 36% to ₹925 crore.
Profit decline outpaces revenue fall
The earnings figures show a much sharper drop in profitability than in revenue. Profit after tax stood at ₹1,437 crore in the corresponding period of the previous year, making the latest result a decline of ₹512 crore.
Revenue performance was comparatively steadier, although it still moved lower by 1.5%. The results therefore point to a quarter in which the reduction in reported profit was considerably greater than the change in revenue.
Company calls trade-margin cap positive
Dr. Reddy’s said the cap on trade margins was a positive development. The company’s statement, as reported with its quarterly results, links its view on the measure to the period’s business update, although no further details were provided.
The second-quarter figures give investors two key metrics to track: the modest decline in revenue and the larger contraction in profit after tax. Further information on the company’s performance was not provided.
Key figures
- Q2 FY2027 revenue: ₹8,671 crore
- Revenue change: down 1.5%
- Q2 FY2027 profit after tax: ₹925 crore
- Profit after tax in the previous year: ₹1,437 crore
- Profit decline: 36%
Dr. Reddy’s quarterly update highlights a significant fall in profit alongside a smaller revenue decline, while the company described the cap on trade margins as positive.